Clinical observation of Huoxue Fangsai decoction on improving the postoperative symptoms of elderly diabetes patients with Qi Deficiency and Phlegm Stasis after endovascular therapy of lower extremity
Objective To investigate the effects of Huoxue Fangsai decoction on the clinical symptoms of elderly diabe-tes patients with Qi Deficiency and Phlegm Stasis after endovascular therapy of lower extremity.Methods 88 elderly patients with type 2 diabetic foot who underwent endovascular therapy of lower extremity in Second Affiliated Hospital of Tianjin Uni-versity of Traditional Chinese Medicine from September 2019 to September 2020 were selected and divided into control group and observation group by random numerical table method,with 44 cases in each group.The control group received routine treatment after operation,and the observation group was treated with Huoxue Fangsai decoction on the basis of the control group.Both groups were treated for 2 weeks.The clinical efficacy,percutaneous partial pressure of oxygen,limb edema and symptom score were compared between the two groups after treatment.The levels of serum interleukin-6(IL-6),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)were compared between the two groups before treatment and 2 weeks af-ter treatment.Results After 2 weeks of treatment,the effective rate of the observation group was significantly higher than that of the control group(P＜0.05),the percutaneous oxygen partial pressure level was significantly higher than that of the control group(P＜0.05),the score of limb edema was significantly lower than that of the control group(P＜0.05),the score of sin-gle symptoms(pain and cold sensation)of the foot was lower than that of the control group(P＜0.05),and the expression levels of CRP,IL-6 and TNF-α were lower than those of the control group(P＜0.05 or P＜0.01).Conclusion Huoxue Fangsai decoction can significantly improve the clinical symptoms of elderly patients with diabetes after endovascular therapy of lower limbs,and its mechanism may be related to inhibiting the expression of inflammatory factors IL-6,TNF-α and CRP.
国家科技期刊平台
NSTL
万方数据
